404 related articles for article (PubMed ID: 29900565)
1. In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody.
Reid J; Zamuner S; Edwards K; Rumley SA; Nevin K; Feeney M; Zecchin C; Fernando D; Wisniacki N
Br J Clin Pharmacol; 2018 Oct; 84(10):2280-2291. PubMed ID: 29900565
[TBL] [Abstract][Full Text] [Related]
2. Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis.
Denton CP; Del Galdo F; Khanna D; Vonk MC; Chung L; Johnson SR; Varga J; Furst DE; Temple J; Zecchin C; Csomor E; Lee A; Wisniacki N; Flint SM; Reid J
Rheumatology (Oxford); 2022 Dec; 62(1):234-242. PubMed ID: 35583273
[TBL] [Abstract][Full Text] [Related]
3. Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti- oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo-controlled trials.
Choy EH; Bendit M; McAleer D; Liu F; Feeney M; Brett S; Zamuner S; Campanile A; Toso J
Arthritis Res Ther; 2013 Sep; 15(5):R132. PubMed ID: 24286335
[TBL] [Abstract][Full Text] [Related]
4. CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6
Bouma G; Zamuner S; Hicks K; Want A; Oliveira J; Choudhury A; Brett S; Robertson D; Felton L; Norris V; Fernando D; Herdman M; Tarzi R
Br J Clin Pharmacol; 2017 Sep; 83(9):1976-1990. PubMed ID: 28295451
[TBL] [Abstract][Full Text] [Related]
5. Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Study of the Penetration of a Monoclonal Antibody Combination (ASN100) Targeting
Magyarics Z; Leslie F; Bartko J; Rouha H; Luperchio S; Schörgenhofer C; Schwameis M; Derhaschnig U; Lagler H; Stiebellehner L; Firbas C; Weber S; Campanaro E; Jilma B; Nagy E; Stevens C
Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31138568
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability After Subcutaneous Administration of Tozorakimab in Healthy Chinese Participants.
Li Y; Zhang H; Pandya H; Miao L; Reid F; Jimenez E; Sadiq MW; Moate R; Lei A; Zhou XH; Kell C; Ding J; Zhang G; Zhao L; Ge X
Clin Pharmacol Drug Dev; 2024 Jun; 13(6):665-671. PubMed ID: 38523487
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1 Single-Ascending-Dose Trial in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravenous PNT001, a Novel Mid-domain Tau Antibody Targeting cis-pT231 Tau.
Luca W; Foster K; McClure K; Ahlijanian MK; Jefson M
J Prev Alzheimers Dis; 2024; 11(2):366-374. PubMed ID: 38374743
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
[TBL] [Abstract][Full Text] [Related]
10. Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.
Ellis J; van Maurik A; Fortunato L; Gisbert S; Chen K; Schwartz A; McHugh S; Want A; Santos Franco S; Oliveira JJ; Price J; Coles A; Brown K; Su D; Craigen JL; Yang J; Brett S; Davis B; Cheriyan J; Kousin-Ezewu O; Gray F; Thompson PW; Fernando D
Br J Clin Pharmacol; 2019 Feb; 85(2):304-315. PubMed ID: 30161291
[TBL] [Abstract][Full Text] [Related]
11. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.
Kretsos K; Golor G; Jullion A; Hickling M; McCabe S; Shaw S; Jose J; Oliver R
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):388-95. PubMed ID: 27129012
[TBL] [Abstract][Full Text] [Related]
12. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
[TBL] [Abstract][Full Text] [Related]
13. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
Chowdary P; Lethagen S; Friedrich U; Brand B; Hay C; Abdul Karim F; Klamroth R; Knoebl P; Laffan M; Mahlangu J; Miesbach W; Dalsgaard Nielsen J; Martín-Salces M; Angchaisuksiri P
J Thromb Haemost; 2015 May; 13(5):743-54. PubMed ID: 25641556
[TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, Pharmacodynamics, and Safety of E6011, a Novel Humanized Antifractalkine (CX3CL1) Monoclonal Antibody: A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study.
Tabuchi H; Katsurabara T; Mori M; Aoyama M; Obara T; Yasuda N; Kawano T; Imai T; Ieiri I; Kumagai Y
J Clin Pharmacol; 2019 May; 59(5):688-701. PubMed ID: 30575978
[TBL] [Abstract][Full Text] [Related]
16. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study.
Nemoto O; Furue M; Nakagawa H; Shiramoto M; Hanada R; Matsuki S; Imayama S; Kato M; Hasebe I; Taira K; Yamamoto M; Mihara R; Kabashima K; Ruzicka T; Hanifin J; Kumagai Y
Br J Dermatol; 2016 Feb; 174(2):296-304. PubMed ID: 26409172
[TBL] [Abstract][Full Text] [Related]
17. Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.
Playford EG; Munro T; Mahler SM; Elliott S; Gerometta M; Hoger KL; Jones ML; Griffin P; Lynch KD; Carroll H; El Saadi D; Gilmour ME; Hughes B; Hughes K; Huang E; de Bakker C; Klein R; Scher MG; Smith IL; Wang LF; Lambert SB; Dimitrov DS; Gray PP; Broder CC
Lancet Infect Dis; 2020 Apr; 20(4):445-454. PubMed ID: 32027842
[TBL] [Abstract][Full Text] [Related]
18. Vedolizumab Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability Following Administration of a Single, Ascending, Intravenous Dose to Healthy Volunteers.
Rosario M; Wyant T; Leach T; Sankoh S; Scholz C; Parikh A; Fox I; Feagan BG
Clin Drug Investig; 2016 Nov; 36(11):913-923. PubMed ID: 27422740
[TBL] [Abstract][Full Text] [Related]
19. A Phase I Study to Assess the Effect of Speed of Injection on Pain, Tolerability, and Pharmacokinetics After High-volume Subcutaneous Administration of Gantenerumab in Healthy Volunteers.
Portron A; Jordan P; Draper K; Muenzer C; Dickerson D; van Iersel T; Hofmann C
Clin Ther; 2020 Jan; 42(1):108-120.e1. PubMed ID: 31883703
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects.
Li Z; Radin A; Li M; Hamilton JD; Kajiwara M; Davis JD; Takahashi Y; Hasegawa S; Ming JE; DiCioccio AT; Li Y; Kovalenko P; Lu Q; Ortemann-Renon C; Ardeleanu M; Swanson BN
Clin Pharmacol Drug Dev; 2020 Aug; 9(6):742-755. PubMed ID: 32348036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
